Hepatitis C virus (HCV) is a potentially life-threatening virus that primarily affects the liver, but is also responsible for extra-hepatic manifestations such as porphyria, increased risk of lymphoma and diabetes. The introduction of direct-acting antiviral (DAA) therapies, which can cure HCV in the majority of patients, represents a major advance – and all Australians living with HCV should now be considered for DAA therapy. However, 121,560 people were estimated to still living be living with chronic HCV at the end of 2019 highlighting the need for improved diagnosis and treatment uptake.
This 1-hour RACGP accredited activity aims to empower GPs to implement a simple, evidence-based approach to identify and manage patients with HCV. It features two cases studies.
This program is supported by an independent and unrestricted educational grant by Gilead.